|
WO2021011807A1
|
|
Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
|
|
WO2021011808A1
|
|
Cardiac sarcomere inhibitor oral formulations
|
|
WO2021011809A1
|
|
Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
|
|
WO2020264358A1
|
|
Polymorphs of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
|
|
AU2019328556A1
|
|
Cardiac sarcomere inhibitors
|
|
WO2020005888A1
|
|
Cardiac sarcomere inhibitors
|
|
WO2020005887A1
|
|
Cardiac sarcomere inhibitors
|
|
CN111757875A
|
|
Dihydrobenzofuran and indene analogs as inotropic agents
|
|
BR112020013020A2
|
|
methods for preparing compounds, and, compounds
|
|
US2016289211A1
|
|
Certain heterocycles, compositions thereof, and methods for their use
|
|
EP3137622A1
|
|
Methods of reducing decline in vital capacity
|
|
US2014303366A1
|
|
Methods for preparing substituted imidazo[4,5-b]pyrazines
|
|
NZ733721A
|
|
Methods for improving resistance to skeletal muscle fatigue
|
|
MX2014012179A
|
|
Improving resistance to skeletal muscle fatigue.
|
|
MX2014011881A
|
|
Methods for improving diaphragm function.
|
|
NZ718896A
|
|
Methods for improving diaphragm function
|
|
EA028060B1
|
|
Combination amyotrophic lateral sclerosis (als) therapy
|
|
MX2014000455A
|
|
Combination als therapy.
|
|
AU2011253934A1
|
|
Substituted urea derivatives for treating cardiac diseases
|
|
EP2582682A1
|
|
Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension
|
